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Objective: To evaluate aggrecanase activity after traumatic knee injury in a rat model by measuring the
level of aggrecanase-generated Ala-Arg-Gly-aggrecan (ARG-aggrecan) fragments in synovial ﬂuid, and
compare with ARG-aggrecan release into joint ﬂuid following human knee injury. To evaluate the effect
of small molecule inhibitors on induced aggrecanase activity in the rat model.
Method: An enzyme-linked immunosorbent assay (ELISA) was developed tomeasure ARG-aggrecan levels
in animal and human joint ﬂuids. A rat model of meniscal tear (MT)-induced joint instability was used to
assess ARG-aggrecan release into joint ﬂuid and the effects of aggrecanase inhibition. Synovial ﬂuids were
also obtained from patients with acute joint injury or osteoarthritis and assayed for ARG-aggrecan.
Results: Joint ﬂuids from human patients after knee injury showed signiﬁcantly enhanced levels of
ARG-aggrecan compared to uninjured reference subjects. Similarly, synovial ﬂuid ARG-aggrecan levels
increased following surgically-induced joint instability in the rat MT model, which was signiﬁcantly
attenuated by orally dosing the animals with AGG-523, an aggrecanase speciﬁc inhibitor.
Conclusions: Aggrecanase-generated aggrecan fragments were rapidly released into human and rat joint
ﬂuids after injury to the knee and remained elevated over a prolonged period. Our ﬁndings in human and
preclinical models strengthen the connection between aggrecanase activity in joints and knee injury and
disease. The ability of a small molecule aggrecanase inhibitor to reduce the release of aggrecanase-
generated aggrecan fragments into rat joints suggests that pharmacologic inhibition of aggrecanase
activity in humans may be an effective treatment for slowing cartilage degradation following joint injury.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The destruction of articular joint cartilage is a hallmark of
human arthritic diseases. Acute or chronic joint injury results in an
imbalance between cartilage matrix synthesis and degradation.
Cartilage breakdown following joint injury is reﬂected by an
immediate signiﬁcant increase in cleavage products of cartilage
matrix proteins in the synovial ﬂuid1,2. Concentrations of these
molecular fragments remain elevated in the joint ﬂuid for long
periods but gradually decline over time. Degradative enzymes and
breakdown products in the contra-lateral (CL) uninjured knee may
also increase, suggesting that some responses to injury are systemicPriya S. Chockalingam, Tissue
Drive, Cambridge, MA 02140,
.S. Chockalingam).
s Research Society International. Paswell as local3. Elevated releaseofmatrixproteins into the jointﬂuid
has been shown also in animal models of joint disease or injury4,5.
Increased expression and activity of catalytic enzymes such as
aggrecanases and matrix metalloproteases (MMPs) result in the loss
of aggrecan and collagen, respectively from the cartilage matrix6,7.
Aggrecan cleavage at the E373eA374 [E392eA393, based on Accession
numbers (Swiss-Prot:P16112) forhumanand (Swiss-Prot:P07897) for
rat] bondof the interglobulardomain (IGD)byaggrecanases results in
the release of large sulfated glycosaminoglycan (sGAG)-substituted
Ala-Arg-Gly-aggrecan (ARG-aggrecan) fragments which diffuse out
of the cartilage matrix, and aggrecanase-generated aggrecan frag-
mentshavebeen identiﬁed insynovialﬂuids fromosteoarthritic, joint
injury, and inﬂammatory joint disease patients8e10.
In the current study we describe a novel assay to detect
ARG-aggrecan fragments using commercially available reagents. Our
results conﬁrm and extend previous ﬁndings that ARG-aggrecan
levels are increased in joint ﬂuid of patients following traumaticublished by Elsevier Ltd. All rights reserved.
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rat meniscal tear (MT) model. This animal model therefore serves to
mimic human joint injury, enabling preclinical investigation of the
role of post-traumatic aggrecanase activity. In addition, we show the
potential for aggrecanase inhibition to prevent the release of aggre-
canase-cleaved aggrecan into synovial ﬂuid in the rat MT model.
Methods
Human synovial ﬂuid samples
Human knee synovial ﬂuids (n¼ 144) were obtained without
lavage andwere from LundUniversity, Sweden from a cross-sectional
convenience cohort with informed patient consent and approval of
the Lund University Ethics Committee. Diagnosis was made by
arthroscopy, radiography, assessment of joint ﬂuid and clinical
examination. Diagnostic groups were knee healthy references (REF;
n¼ 8), knee anterior/posterior cruciate ligament rupture, with or
without concomitant meniscus lesions (ACL/PCL; n¼ 56), isolated
knee meniscus injury (MI; n¼ 69), and knee osteoarthritis (OA;
n¼ 11). ThemeanOAgrades of these groupsbasedonDahlberg et al.11
are summarized in Table I. ARG-aggrecan was quantiﬁed in these
samples at appropriate dilutions as described. Sampleswere tested at
three different dilutions and results averaged for these assays.
Aggrecanase inhibitor
AGG-523 is a small molecule compound that was developed by
structure-baseddesign (USPatent Application PublicationNo. 2007/
0043066), and is a reversible, non-hydroxamate, zinc-binding
selective inhibitor of ADAMTS4 andADAMTS5. The inhibitionproﬁle
of the compound is summarized in Table II. The potency of AGG-523
to inhibit the enzymatic activityofmetalloproteasesor aggrecanases
was tested in a continuous Fluorescent Resonance Energy Transfer
(FRET) assay. The FRET assay uses speciﬁc substrates and protocols
designed for individual enzymes12e14. The Ki (inhibitor dissociation
constant) values for ADAMTS4 andADAMTS5weredeterminedwith
a continuous ﬂuorescence polarization (FP) assay15.
Rat MT model
Male Lewis rats weighing approximately 300 g were obtained
from Charles River Laboratories (Wilmington, MA). In the time
course study of ARG-aggrecan release, rats underwent medial MT
surgery in the right knee to induce joint instability leading to carti-
lage degeneration as described16,17. The animals were euthanized atTable I
ARG-aggrecan levels in human synovial ﬂuids
Study group ACL/PCL
(0e12 weeks)
ACL/PCL
(12e52 weeks)
ACL/PCL
(>1 year)
Mean sampling time (range)
in weeks post-injury/onset
1 (0e6) 25 (13e48) 279 (57e1115)
No. of subjects 26 8 22
Mean age (range) in years 25 (14e50) 31 (17e50) 31 (14e53)
Mean (range) OA grade 1 (1e3) 2 (1e3) 3 (1e6)
% Male 62 63 68
Mean (range) ARG-aggrecan
(mg/ml)
148 (19e588) 49 (9e195) 36 (2e107)
95% conﬁdence intervals for
ARG-aggrecan
95, 202 2, 96 22, 51
Mean fold difference over Ref. 13.6 4.5 3.3
P value (compared to Ref.) <0.0001 0.0666 0.0575
Ref.¼ knee healthy references; ACL/PCL¼ knee anterior/posterior cruciate ligament ruptu
ARG-aggrecan are shown as averages with the range. Grades of 0e1 represent normal
graphic changes. Mean ARG-aggrecan is the mean of averaged ARG-aggrecan values for
based on the ANOVA of log transformed ARG-aggrecan values.different times after surgery (4 dayse8 weeks, n¼ 10/time point).
Synovial ﬂuid lavages and serum were collected. Five naive animals
per time point were also included. In the study to determine the
effect of speciﬁc aggrecanase inhibition on ARG-aggrecan release,
animals (6e7 per group/time point) were dosed 1 week after medial
MT surgerywith three doses [twice a day (BID) dosing over 2 days] of
vehicle [0.5% methyl cellulose/2% Polysorbate (Tween) 20] or
1000 mg/kg AGG-523. Synovial ﬂuid lavageswere collected from the
knees at 2, 4, 6, or 8 h following the last dose. ARG-aggrecan levels
were determined in synovial ﬂuid lavage collected from surgery
knees with CL joint ﬂuids as controls. Serum and synovial ﬂuid urea
levels in each animal were used to correct ARG-aggrecan values for
dilution18. These studies were performed under the approval of
Pﬁzer’s Institutional Animal Care and Use Committee.ARG-aggrecan enzyme-linked immunosorbent assay (ELISA)
Aggrecanwas prepared by extraction of sliced rat cartilage in 4 M
Guanidine HCl, 50 mM sodium acetate pH 5.8 containing protease
inhibitor followed by extensive dialysis. Aggrecan was cleaved with
rhADAMTS4 prepared at Pﬁzer19 (2.5 mg rADAMTS4/mg aggrecan) in
50mM Tris, pH 7.3, 100 mM NaCl, 5 mM CaCl2, and deglycosylated
with 0.0025 U chondroitinase ABC (Sigma, St Louis, MO), 0.0025 U
Keratanase I and 0.00025 U Keratanase II (Seikagaku America, Fal-
mouth, MA) per 10 mg sGAG (aggrecan) at 37C for 3 h and used as
a standard. Human aggrecan standard was prepared using protocols
described20 with some modiﬁcations. Brieﬂy, 1 g of human OA carti-
lage was pulverized under liquid nitrogen and suspended in 10 ml of
4 M guanidine HCl, 50 mM sodium acetate pH 5.8 containing 1
protease inhibitor cocktail and extracted for 48 h at 4C. Themixture
was then centrifuged at 3000 rpm for 10 min, supernatant separated
onaCsClgradient (100,000g for72 hat4C). Thebottom1/3portion
of the divided sample was dialyzed against Millipore water in the
presence of 1 inhibitor and cleaved with rhADAMTS4 as described
above. Anestimatedmolecularweightof 1.5106 g/molwasused for
aggrecan standard based on Struglics et al.9 The concentration of rat
and human aggrecan standards was expressed as the amount of
proteoglycan measured prior to deglycosylation. Proteoglycan was
determinedby the sGAGassay (Kamiya Biomedical Company, Seattle,
WA), a quantitative dye-binding assay for the in vitro analysis of
sGAGs that uses chondroitin sulfate as the standard21.
Monoclonal anti-human aggrecan antibody AHP0022
(Invitrogen, Carlsbad, California) that recognizes an epitope in both
the G1 and G2 globular domains of aggrecan was used as the
capture antibody with monoclonal ARG-aggrecan speciﬁc antibody
BC-3 (Abcam, Cambridge, UK) for detection in the ELISA. BC-3 wasMI
(0e12 weeks)
MI
(12e52 weeks)
MI
(>1 year)
OA Ref.
3 (0e12) 24 (13e40) 418 (52e1926) 189 (0e481) e
27 22 20 11 8
34 (18e59) 35 (16e55) 45 (28e70) 67 (39e86) 28 (17e42)
2 (0e5) 2 (0e3) 3 (1e8) 8 (3e9) 1 (0e1)
93 86 70 45 75
88 (7e394) 23 (2e94) 16 (2e85) 39 (6e133) 11 (5e19)
52, 125 13, 34 7, 25 14, 63 7, 15
8.1 2.1 1.4 3.5 e
0.0001 0.3683 0.9734 0.0461 e
re; MI¼ kneemeniscus injury; and OA¼ knee OA. Sampling time, age, OA grade and
cartilage, 2e5 represent arthroscopic cartilage changes, and 6e10 represent radio-
subjects within a group tested in triplicates. P values are from a paired comparison
Table II
Inhibition proﬁle of AGG-523
Enzyme IC50 (mM)
ADAMTS4 <0.03 (Ki¼ 0.006)
ADAMTS5 0.04 (Ki¼ 0.1)
MMP-1 >200
MMP-2 9.58
MMP-3 15% inhibition @ 25
MMP-7 4% inhibition @ 25
MMP-8 3.5
MMP-9 No inhibition @ 25
MMP-12 1.96
MMP-13 >50
MMP-14 >200
TACE >10
IC50s were determined by FRET assays using synthetic peptide
for the respective enzyme containing a ﬂuorescent group
(7-methoxycoumarin or 2-aminobenzoyl) that was quenched
by energy transfer to 2,4-dinitrophenyl. Ki for ADAMTS4 and
ADAMTS5 were determined by the FP assay. TACE-Tumor
Necrosis Factor-alpha converting enzyme.
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for speciﬁc binding of AHP0022 and BC-3 to human aggrecan and
synovial ﬂuid, 3e5 mg of human ARG-aggrecan standard
(rhADAMTS4 digested human A1D1 fraction of cartilage) and
a D1 fraction of synovial ﬂuids pooled from OA patients9 were
deglycosylated, separated on a 3e8% Tris-acetate sodium dodecyl
sulfate (SDS) gel, blotted onto a polyvinylidene ﬂuoride (PVDF)
membrane and probed with AHP0022, BC-3, or AGG-C119.
BC-3 was conjugated to horseradish peroxidase (HRP) using the
HRP conjugation kit (Alpha Diagnostic International Inc., San
Antonio, Texas). A 10 mg/ml stock of AHP0022 in phosphate buff-
ered saline (PBS) was prepared and 96-well plates (Costar) were
coated at 1 mg/well. Plates were incubated overnight at 4C, washed
3 times with 300 ml of PBST (PBSþ 0.05% Tween), and blocked with
300 ml of 2% bovine serum albumin (BSA) in PBST for 1.5 h at room
temperature (RT). Plates were washed 3 times with PBST and used
immediately or stored at 4C.
Synovial ﬂuids were centrifuged at 14,000g at 4C, followed by
addition of 0.02 U of Chondroitinase ABC, 0.02 Uof Keratanase I, and
0.001 Uof Keratanase II per 100 ml of synovialﬂuid and incubation at
37C for 3 h.100 ml of appropriatelydiluted (1:50or lowerdilution in
PBS for rat samples; 1:50 or higher dilution in PBS for human
samples) deglycosylated synovial ﬂuid was added to AHP0022-
coated plates in duplicate; 100 ml of the respective aggrecan stan-
dards were also added at a range of 0.078e5.0 mg/ml proteoglycan
(approximately 0.052e3.333 pmol/ml assuming an average aggre-
can molecular weight of 1.5106 Da) and incubated for 2 h at RT
with shaking. The plates were thenwashed three times with 300 ml
of PBST, and100 ml of BC-3-HRPwas added at aﬁnal concentration of
50 ng/ml in PBST and incubated for 1.5 h at RT. Plates were washed
four timeswithPBST; and100 ml of tetramethylbenzidine (TMB)One
Component HRP micro well substrate (Biofx Laboratories, Owings
Mills, MD) was added for 15 min. The reaction was stopped by
addition of 100 ml of 0.25 M sulfuric acid. The plates were read at
450 nm with a reference ﬁlter of 540 nm. Absorbance values from
the standards were ﬁtted to a 4-parameter logistic model and ARG-
aggrecan levels calculated from the standard curve. Sample dilution
was determined for a linear detection and to maintain total
proteoglycan at or below 500 ng/well (5 mg/ml).
Speciﬁcity of detection and technical validation of the ELISA
Speciﬁcity of the assay was determined by analyzing rat/human
aggrecan (1) cleaved by rhADAMTS4 and deglycosylated; (2) cleaved
by rhADAMTS4 and non-deglycosylated; (3) cleaved by MMP-13(rhMMP-13 catalytic domain prepared in house; 2.5 mg MMP-13/mg
aggrecan) and deglycosylated; and (4) uncleaved and deglycosy-
lated. Aggrecan standards incubated in PBS- or mouse IgG-coated
wells were tested as negative controls. To further conﬁrm speciﬁcity,
two synovial ﬂuids each for rat and humanwere immunodepleted of
aggrecan using AHP0022 or AHP0012, an anti-aggrecan antibody
that binds to the keratan sulfate chains, and then analyzed in the
ELISA. Protein-G Dynabeads (Invitrogen) were used following
manufacturer’s protocol for immunoprecipitation purposes (20 mg
antibody was used for conjugation; 200 ml of synovial ﬂuid was used
for depletion). Mouse IgG was used as a negative control in immu-
nodepletion experiments. Toyopearl DEAE-650S (Tosoh Bioscience,
Montgomeryville, PA) was also used as an alternative method to
deplete aggrecan in synovial ﬂuid. The complete loss of aggrecan in
depleted samples was conﬁrmed by measuring total proteoglycan.
Quantiﬁcation of rat ARG-fragments was also performed using the
liquid chromatography-tandem mass spectrometry (LC-MS/MS)
method as described below.
In order to determine spike-in recovery of aggrecan, two rat
synovial ﬂuids diluted at 1:5, 1:10, or 1:20 were spiked with 50 or
100 ng of ARG-aggrecan standard and analyzed in the ELISA.
Within-assay precision for the ARG-ELISA was measured by
assaying a pooled rat synovial ﬂuid sample 96 times across the
wells of a 96-well plate. Between-assay precision for the ARG-ELISA
was determined by deglycosylating and assaying two rat synovial
ﬂuids four different times/days with respective standards. Similar
experiments were also conducted with human synovial ﬂuids for
the technical validation of human sample detection.
ARG-aggrecan quantitation using LC-MS/MS
Amultidimensional (immunoafﬁnity/reversed-phase) LC-MS/MS
analysis of ARG-aggrecan in rat synovial ﬂuid lavage was done for
speciﬁc samples following protocols described22. Brieﬂy, a repre-
sentative peptide (ARGNVIL) was created by digestion with chymo-
trypsin and quantiﬁed as a measure of aggrecan in synovial ﬂuid.
Although the speciﬁcity of chymotrypsin is relatively broad23,24, the
ability to cleave on the C-terminal side of aromatic and large
hydrophobic residues was exploited to reproducibly cleave aggrecan
after leucine residues and produce peptides suitable for LC-MS/MS. A
slightly longer deuterated internal standard peptide ARGN(d8)VIL-
TAK was added to correct for both digestion efﬁciency and injection
volumes. Both the heavy and light forms of the peptide, ARGNVIL
were speciﬁcally detected by monitoring high-performance liquid
chromatography (HPLC) elution times and ionpairs corresponding to
the speciﬁc multiple reaction monitoring (MRM) pairs (371.5/470.3).
The digested synovial ﬂuid samples were enriched on an antibody
column (BC-3) and analyzed by LC-MS/MS. Peptide abundances
were determined by comparing the LC-MS/MS peak areas of the
analytes to those of deuterated internal standards. Standard curves
were prepared at concentrations ranging from 1 to100 pg/ml
(0.001e0.135 pmol/ml based on the MW of 741 Da for the peptide).
Statistical analysis
One-way Analysis of Variance (ANOVA) of log transformed
ARG-aggrecan values from human and rat synovial ﬂuids was
performed to test for statistical signiﬁcance. Spearman’s rank order
was used for correlation analysis.
Results
ARG-aggrecan ELISA
ADAMTS4 digested and deglycosylated aggrecan fragments
bound by anti-aggrecan antibody AHP0022 in the 96-well
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Fig. 1. (A) Western analysis of antibody binding to aggrecan: Human ARG-aggrecan standard and a D1 fraction of synovial ﬂuid pool from OA patients were deglyco-
sylated, separated on a 3e8% Tris-acetate SDS gel, blotted onto a PVDF membrane, and probed with AHP0022 (1:500), BC-3 (1:2000), or AGG-C1 (1:3000). C¼Human
ARG-aggrecan standard; SF¼D1 fraction of synovial ﬂuid pooled from OA patients. C and SF were loaded at the equivalent of 3 mg sGAG for AHP0022 and BC-3 analysis. 5 mg
sGAG of C was loaded for AGG-C1 analysis. ARGS-G2-GVA in species 5 was observed only in the synovial ﬂuid pool from OA patients and its identity was conﬁrmed by anti-
GVA analysis (data not shown; anti-GVA kindly provided by Dr Struglics, Lund). (B) Speciﬁcity of the ELISA: Rat aggrecan cleaved with ADAMTS4, deglycosylated
(diamond); Uncleaved aggrecan, deglycosylated (circle); MMP-13 cleaved, deglycosylated (square); ADAMTS4 cleaved but not deglycosylated aggrecan (cross) were tested in
the ARG-ELISA.
P.S. Chockalingam et al. / Osteoarthritis and Cartilage 19 (2011) 315e323318format sandwich ELISA were detected by antibody BC-3, which
recognizes only ARG-positive aggrecan generated from speciﬁc
aggrecanase cleavage in the IGD of aggrecan. Absorbance values
from the standards at a range of 0.078e5.0 mg of aggrecan
(glycosaminoglycan)/ml were ﬁtted to a 4-parameter logistic
model (R2¼1.0). The range of detection for the assay
was 0.1e5.0 mg/ml (or 0.067e3.333 pmol/ml) aggrecan. The
output signal was concentration dependent up to 5 mg/ml total
proteoglycan.Speciﬁcity of the ELISA method
In theWestern analysis of human aggrecan standard and synovial
ﬂuid, BC-3 and AHP0022 recognized a 310 kD ARGS-G2-SELE band
[Fig. 1(A); species 1], and 120e160 kDARGS-G2-CS1 bands [Fig. 1(A);
species 2 and 3] similar to already reported ARGS-aggrecan frag-
ments9. An additional 69 kD band, reactive with both BC-3 and
AHP0022, was detected in puriﬁed synovial ﬂuid [Fig. 1(A); species
5]; plausibly an ARGS-G2-GVA fragment based on its reactivity with
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Fig. 2. Correlation between the ARG-aggrecan ELISA and the LC-MS/MS analysis for
ARG-aggrecan quantitation in rat synovial ﬂuid lavage samples from the rat MT model
(n¼ 28, rs from Spearman¼ 0.95, P< 0.0001).
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shown)25. The G1-TEGE fragments generated by ADAMTS4 digestion
of the standard were reactive with both AGG-C1 (anti-TEGE)19, and
AHP0022 [Fig. 1(A); species 4]. This data indicates that AHP0022 is
binding to G1 and/or G2-positive aggrecan, and that it has the
capability of capturing all ARGS-positive aggrecan found in the
standard and in this puriﬁed synovial ﬂuid.
The ELISA detected ADAMTS4-cleaved rat/human aggrecan but
not intact aggrecan or MMP-13 cleaved aggrecan conﬁrming the
speciﬁcity of the assay [rat aggrecan data shown in Fig. 1(B)]. Degly-
cosylated standards (0.078e5.0 mg/ml) plated on PBS- ormouse IgG-
coated wells served as negative controls and did not produce any
optical density (OD) values in the ELISAconﬁrming speciﬁc bindingof
aggrecan to AHP0022-coated plates. Non-deglycosylated rat/human
synovial ﬂuids produced insigniﬁcant or no absorbance values. The
binding of BC-3 to aggrecan required deglycosylation, whereas
AHP0022 bound to both glycosylated and deglycosylated forms of
aggrecan. This was determined in a direct binding assay where
human aggrecan standard (deglycosylated or non-deglycosylated)
was coated onto a plate followed by incubation of BC-3 or AHP0022,
addition of HRP-conjugated anti-mouse secondary antibody, and
detection. This was further evidenced by a recent publication26. The
binding of AHP0022 to the core proteinwas conﬁrmed by testing the
ability of the antibody to bind to recombinant human aggrecan
G1-IGD-G2 (R&D Systems, Minneapolis, MN) in the ELISA (data not
shown).Whenaggrecan in synovialﬂuidswasdepletedwith theanti-
aggrecan antibody, AHP0022 or AHP0012, or using DEAE-650S,100%
loss of ARG-aggrecan signalwas observed in the assay conﬁrming the
speciﬁcity of detection.
Technical validation of the ELISA
The mean spike recovery of rat aggrecan at dilutions of 1:5, 1:10,
and 1:20 was 92% with a range of 82e96% for rat synovial ﬂuids
tested. The mean spike recovery of human aggrecan at dilutions of
1:50, 1:100, and 1:200 was 102% with a range of 74e134% for human
synovial ﬂuids tested. The coefﬁcient of variation (CV) for within-
assay precision measured by assaying a rat or a human synovial ﬂuid
96 times across the sameplatewas2.4%. Thebetween-assayprecision
for rat samples was measured by assaying two rat joint ﬂuids four
different times with respective standards on separate days including
independent sampling and deglycosylation. The CV of two samples
was determined to be 3.5% and 3.3%, respectively. The between-assay
precision for human samples was similarly determined by assaying
fourhuman jointﬂuids; theCVwere1.7,1.7, 2.5, and2.0%, respectively.
ARG-aggrecan ELISA vs LC-MS/MS
Synovial ﬂuid lavage samples (n¼ 28) from a 1-week-rat MT
study tested in the ELISAwere also analyzed in the LC-MS/MS assay.
ELISA data measured as mg/ml ARG-aggrecan was converted to
pmol/ml assuming an average aggrecan molecular weight of
1.5106 Da. Similarly, LC/MS-MS data quantiﬁed as ng/ml analyte
was converted to pmol/ml based on themolecular weight of 741 Da
for the ARGNVIL standard peptide. A signiﬁcant correlation was
observed between measured ARG-aggrecan levels in these two
assays as determined by the Spearman’s rank order correlation
(rs¼ 0.95; Fig. 2) conﬁrming the speciﬁcity of detection in the ELISA
method.
ARG-aggrecan in the joint ﬂuid of human patients with knee injury/
disease
ARG-aggrecan in human synovial ﬂuids showed a wide range of
concentrations from 2 to 588 mg/ml. Signiﬁcantly higher levels ofARG-aggrecan compared to reference subjects were observed in
ACL/PCL 0e12 weeks post-injury, MI 0e12 weeks post-injury, and
OA synovial ﬂuids. The observed increases in the ARG-aggrecan
levels of ACL/PCL and MI patients compared to reference levels
decreased over time following joint injury (Table I).
ARG-aggrecan in rat synovial ﬂuids and effect of aggrecanase
inhibition
There was a signiﬁcant increase in ARG-aggrecan levels in
operated unstable right knees (4-fold) 4 days and 1 week after
surgery as compared to un-operated CL left knees or to naive
animals (left and right knees). The signiﬁcant increase in ARG-
aggrecan levels in unstable knees compared to CL knees or naive
animals was maintained up to 8 weeks post-surgery (Fig. 3).
When rats were treated with three doses of 1000 mg AGG-523/
kg BID, starting a week after surgery, and synovial ﬂuid lavage
collected 2, 4, 6, or 8 h after last dosing, there was complete inhi-
bition of surgery-induced ARG-aggrecan release in unstable knees
of the inhibitor-treated rats as compared to vehicle-treated rats at 6
and 8 h after last dosing of AGG-523 (Table III). ARG-aggrecan levels
in the surgery knees of AGG-523 treated rats at these time points
were close to or lower than levels observed in the un-operated CL
knees of the vehicle-treated animals. The inhibitions at 2 and 4 h
after last dose were 38% and 78%, respectively, considering a 100%
inhibition for levels similar to ARG-aggrecan in un-operated knees
of vehicle-treated animals. There was a similar reduction in the
basal level of ARG-aggrecan in un-operated CL knees with AGG-523
treatment (Table III).
Discussion
A novel ELISAwas developed to quantify aggrecanase-generated
ARG-aggrecan fragments in both human and rat synovial ﬂuids.
Results from the assay of human samples indicate that aggrecanase
activity was increased signiﬁcantly in the period immediately after
injury, and, although joint ﬂuid levels of ARG-aggrecan decline over
time, they were signiﬁcantly higher than normal levels up to
12 weeks after injury, and showed a trend toward persistence of
raised levels thereafter which was not statistically signiﬁcant. The
levels of ARG-aggrecan in OA patients were similar to the measured
levels in ACL/PCL patients >1 year post-injury (Table I). The same
time-related trends of ARG-aggrecan release following injury were
seen in the rat model, and the capacity to inhibit aggrecanase-
cleaved aggrecan release with a small molecule aggrecanase
inhibitor was demonstrated.
Fig. 3. Time course of ARG-aggrecan release in the rat MT model. Rats were euthanized at different times after surgery (4 dayse8 weeks, n¼ 10 rats/time point). Five naive rats
(10 joints) per time point were also included in the study. For each time point, 10 synovial ﬂuid lavage samples from the right MT, left CL, and naive (N; leftþ right knees) joints were
tested in the ARG-aggrecan ELISA and values corrected for dilution using serum urea levels. Average ARG-aggrecan with the error bars indicating 95% conﬁdence intervals. No
correction was made in statistical testing for naive right-left knees not being independent. P values are included in the graph.
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concentrations in biological samples was reported by Pratta et al.
using a sandwich anti-KS/mAb OA-1 ELISA with proprietary
reagents27. This assay was used in a recent cross-sectional study of
human joint ﬂuids10. However, as discussed by Larsson et al.
a limitation to their ELISA format using anti-keratan sulfate anti-
body for capture could arise from variability in the degree of ker-
atan sulfate substitution in the aggrecan population10.
A similar assay formathasbeenused as oneof the tools toanalyze
samples froma ratmonosodium iodoacetate (MIA)model28 but this
study does not include assay development, validation steps and
assay qualiﬁcation. Consequently, a newermethodwas described by
the same group using BC-3-C2 (optimized BC-3), a proprietary
antibody for quantifying ARG-aggrecan fragments in synovial ﬂuid,
serum and urine26. The ELISA method in our study that has been
developed, validated, clinically qualiﬁed, and speciﬁcity conﬁrmed
using anorthogonal assay format is, however, theﬁrst of its kind thatTable III
Effect of AGG-523 on the release of ARG-aggrecan in the rat MT model
Treatment Right unstable knee
Vehicle 1000 mg/kg AGG-523
2 h 4 h 6 h
No. of animals 7 7 6 6
Mean ARG-aggrecan (mg/ml) 20.9 16.6 12.0 8.4
95% conﬁdence intervals 16.8, 24.9 10.7, 22.4 9.6, 14.4 5.4, 1
P value (compared to vehicle) e 0.1 0.004 0.000
Three oral doses of vehicle or 1000 mg/kg AGG-523 were administered over 2 days and sy
synovial ﬂuid harvested at 6 h after last dosing from 4 rats, and at 8 h after last dosing from
controls. P values are from a paired comparison based on the ANOVA of log transformeddetects ARG-aggrecan fragments in biological samples using
commercially available reagents. Our method is also sensitive and
suitable for testing synovial ﬂuids spanning a wide range of ARG-
aggrecan concentrations (lower limit of approximately 0.1 mg/ml for
rat synovial ﬂuid and 1 mg/ml for human synovial ﬂuid).
Four assumptions have been necessary in the quantiﬁcation of
ARG-aggrecan by ELISA in synovial ﬂuids: (1) Digestion of aggrecan
with rhADAMTS4 rendered a complete conversion of aggrecan
with an intact IGD into C-terminal ARG-aggrecan and N-terminal
TEGE-aggrecan fragments. (2) The proportion of differently sized
aggrecan fragments detected in synovial ﬂuid equals those found in
the standards. (3) All ARG-aggrecan fragments also contain the
G2 domain. (4) All the aggrecan fragments containing both ARG and
G2 have the same molar reactivity with BC-3 and AHP0022, irre-
spective of size, GAG content, and C-terminal truncation.
Binding of AHP0022 to all of the ARG-aggrecan species in
human aggrecan standard and puriﬁed synovial ﬂuid detected byLeft CL knee
Vehicle 1000 mg/kg AGG-523
8 h 2 h 4 h 6 h 8 h
6 7 7 6 6 6
9.0 9.5 5.7 4.8 4.4 4.4
1.4 6.5, 11.5 7.3, 11.6 4.1, 7.4 3.8, 5.8 3.8, 4.9 3.6, 5.1
7 0.0007 e 0.02 0.003 0.003 0.003
novial ﬂuid harvested at the indicated time points post last dose. Of the 7 vehicle rats,
3 rats. Right knees of animals underwent surgery; left non-surgery knees served as
ARG-aggrecan values.
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human aggrecan standard and synovial ﬂuid are captured by
AHP0022 in our assay format. However, two minor MMP cleavage
sites (from in vitro digestion with excess enzyme) in the IGD of
aggrecan have been reported: 384PeV385 and 441DeL442 29,30 which
might result in the loss of G2 domain from ARG-aggrecan frag-
ments that are recognized by AHP0022 in the assay. Even though
G1 fragments reﬂecting cleavage at these sites have not been
reported in human aggrecan preparation cleaved byMMP in vitro or
in human synovial ﬂuids tested9, loss of G2 domain is possible from
some ARG-aggrecan fragments due to multiple MMP cleavages31.
Detection of speciﬁc fragments in the LC-MS/MS method and the
signiﬁcant correlation of ARG-fragments quantiﬁed in these two
assays (Fig. 2) not only conﬁrm speciﬁcity of detection in the ELISA
but also suggest that the ELISA method captures and quantiﬁes all
ARG-aggrecan species similar to a method that involves direct
binding of BC-3 to ARG-positive aggrecan fragments. However, the
discrepancy seen between the ELISA and LC-MS/MS assays could
arise from the different standards (aggrecan puriﬁed from cartilage
with a roughly estimated MW vs speciﬁc synthetic peptide) used in
these assays.
The major advantages of the present method are that it uses
commercially available reagents and that the assay is applicable to
testing synovial ﬂuid from animal joints in addition to human
joints. Homologous aggrecanase cleavage sites and cleavage prod-
ucts have been reported in bovine, equine, porcine, and murine
aggrecan32e35. The applicability of this assay to detect aggrecan
from various species makes it a good candidate to analyze samples
from preclinical animal models. We have detected ARG-aggrecan
fragments in the synovial ﬂuid of non-human primates and guinea
pigs in addition to humans and rats (data not shown).
Transection of the medial meniscus in rats leads to histological
changes consistent with OA as rapidly as 1e2 weeks after surgery,
progressing over time to severe cartilage degeneration16. The
cartilage lesions that occur in this joint instability model are
morphologically similar to those that occur in human OA, although
the rate of development of damage is greatly increased in rats
compared to humans. Induction of OA in rats by surgical tear of the
meniscus thus serves as a relevant animal model representing joint
injury in humans. Importantly, this model has been used to assess
the efﬁcacy of potential therapeutics for OA16,36,37. ARG-aggrecan
release in the rat MT model showed a trend similar to human
subjects following acute joint injury. ARG-aggrecan levels were the
highest immediately after joint instability induction, and elevated
levels weremaintained for several weeks after surgical induction of
instability, albeit with a smaller absolute difference from control
(Fig. 3).
AGG-523 has been extensively studied in phase I safety toxi-
cology studies in mice, rats and dogs. The oral bioavailability was
good in rats (54%), the t1/2 was moderate (4.6 h), and the tmax was
0.25e1 h. Rats were dosed up to 4 weeks at high doses (2000 mg/
kg/day) with no compound-related mortality and no adverse clin-
ical signs, effect on body weight or food consumption. The orally
dosed compound was detected in the plasma, synovial ﬂuid, and
the knee cartilage of the animals. We observed a signiﬁcant inhi-
bition of surgery-induced ARG-aggrecan release into the synovial
ﬂuid in the rat joint injury model by treatment with AGG-523 in
comparison to vehicle treatment (Table III). We also observed
a reduction of ARG-aggrecan release in the CL knees of inhibitor-
treated animals due to a systemic response (5.7e4.4 mg/ml ARG-
aggrecan in AGG-523 treated rats vs 9.5 mg/ml in vehicle-treated
rats). Inhibition of ARG-aggrecan release into surgically injured
knees by systemic administration of AGG-523 in this rat model
conﬁrms the role of aggrecanase activity in injury related cartilage
matrix degradation. However, we acknowledge that the levels inthe surgery-induced knees of inhibitor-treated animals did not
lower to the corresponding levels in their CL knees suggesting
a role for other enzymes in injury related ARG-aggrecan release.
Matrix metalloproteinases and other proteases may contribute to
some degree to the degradation of aggrecan, at least in human
joints38,39. Further, calpain activity on aggrecan could have a role in
joint diseases as calpain generated ARGS-EDLS fragments have
recently been identiﬁed speciﬁcally in the synovial ﬂuid of patients
with acute inﬂammatory arthritis25. We have identiﬁed a calpain
generated ARGS-G2-GVA species in the synovial ﬂuid pool from OA
patients [Fig. 1(A)]. Detailed studies are ongoing to better under-
stand the ratMTmodel in terms of formation and clearance of ARG-
aggrecan in the joint.
GAG content was replenished at early stages of aggrecanase-
mediated aggrecan damage, whereas the loss of structural integrity
was irreversible after collagen damage at later stages of explant
cultures40. In addition to its functional role in cartilage load-bearing,
aggrecan may have a protective role in preventing type II collagen
loss from the cartilage matrix41. Indeed, reduction of aggrecan
catabolism has been shown to abrogate the development of exper-
imental arthritis in ADAMTS5knockout31,32. Blocking cleavage at the
IGD in the knock-in mice diminished aggrecan loss and cartilage
erosion in the OA model. However, only the spread of the OA-like
pathology in the cartilage was curtailed but the focal cartilage
damage was not prevented in the knock-ins42. Furthermore,
ADAMTS4 and ADAMTS5 knockout mice and double knockout mice
are viable, fertile, and demonstrate no gross abnormalities43.
Together, these results warrant further studies of aggrecanase
inhibition as ameans of decreasing cartilage damage in joint disease.
Extensive literature documents the relationship between knee
injury and subsequent OA in humans44e47. Young adults with acute
knee injury have an accelerated risk of developing symptomatic OA
and thus represent an attractive population for disease modifying
interventional studies. Longer term studies of aggrecanase activity
and joint changes in these patients might provide insights as to
how the degradative mechanisms that initiate with traumatic
insult to the knee translate into a progressive disease.
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